Recent advances in treating breast cancer are reaching back to the past to the first known biomarker, human epidermal growth factor, to determine its value in treating patients
HER2- Advanced Breast Cancer Roadmap
Potential diagnostic and prognostic biomarkers for breast cancer: A compiled review - ScienceDirect
Schema of a case study (HER2 positive breast cancer) and the
Treatment of HER2-Low, HR-Positive, and TNBC: A Focus on HER2-Targeted and TROP2–Targeted Therapy
Cancer biomarker - Wikipedia
MLO Hot Clips Medical Laboratory Observer
Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future - ESMO Gastrointestinal Oncology
Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status, BMC Medicine
HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort - Modern Pathology
Pathology Report, Pathologist Melbourne, VIC
Oncology
Oncology
Targeting HER2 expression in cancer: New drugs and new indications
October 2022 Medical Laboratory Observer
